2000 Fiscal Year Final Research Report Summary
Expression cloning of anticancer drug-sensitivity-regulatory molecules in gynecologic malignancy
| Project/Area Number |
11671642
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
TANAKA Tetsuji Osaka City Univ. Med Sch., Assistant Professor, 医学部, 講師 (80275255)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HONDA Ken-ichi Osaka City Univ. Med Sch., Assistant, 医学部, 助手 (40244644)
KAWAMURA Naoki Osaka City Univ. Med Sch., Assistant Prof., 医学部, 講師 (30254410)
HIRAI Kouzo Osaka City Univ. Med Sch., Assistant, 医学部, 助手 (00305616)
OGITA Sachio Osaka City Univ. Med Sch., Professor, 医学部, 教授 (00047086)
UMESAKI Naohiko Osaka City Univ. Med Sch., Assoc. Prof., 医学部, 助教授 (20106339)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Keywords | drug-resistance / expression cloning / differential display |
|---|
| Research Abstract |
In this study, molecular cloning of anticancer drug-resistance-related genes were performed by using various anticancer drug-resistant subclones we have originally established from gynecological cancer cell lines. Moreover, analyses of regulatory mechanisms of anticancer drug-sensitivity in the drug-resistant sublines we established were also examined.
First, we have been applied differential display procedure to RNA extracted from the various drug-resistant subclones. The experiments have not been finished yet. By the differential display method. several candidate genes related to anticancer drug-sensitivity/resistance such as aldehyde dehydrogenase, T-cell leukemia related genes, cytochome C gene and interleukin-13 receptor gene were selected. We are now under investigation of functional analyses of the candidate genes.
Although in fact we have found lots of discovery in drug-resistance mechanisms by analyses of the established drug-resistant sublines, we did not have enough time to publish these results on international journals. On more than one hundred of resistant subclone, we analyzed them by cross-resistance to other anticancer drugs, expression of known drug-resistance-related genes (quantitative Taq-Man RT-PCR), immunocytochemistry and flow cytometry. Chromosomal analyses were also examined.
We are investigating differential expressions of 1,176 genes in the drug-resistance cancer cells by DNA microarray technology. Together with pharmaceutical company which have developed anticancer drugs, we are searching candidate drugs to recover drug-sensitivity in the drug-resistant cells.
|
